Northern Trust
ABVC icon

Northern Trust’s ABVC BioPharma ABVC Stock Holding History

Northern Trust’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.9K Buy
48,643
+16,556
+52% +$20.6K ﹤0.01% 4181
2026
Q1 		$31.1K Hold
32,087
– – ﹤0.01% 4301
2025
Q4 		$68.3K Buy
32,087
+7,266
+29% +$19.5K ﹤0.01% 4219
2025
Q3 		$75.5K Sell
24,821
-12,323
-33% -$37.9K ﹤0.01% 4201
2025
Q2 		$82.6K Buy
37,144
+18,009
+94% +$24.5K ﹤0.01% 4150
2025
Q1 		$20.3K Hold
19,135
– – ﹤0.01% 4336
2024
Q4 		$11.3K Hold
19,135
– – ﹤0.01% 4418
2024
Q3 		$13.1K Hold
19,135
– – ﹤0.01% 4364
2024
Q2 		$14.8K Buy
+19,135
New +$19.6K ﹤0.01% 4352
2023
Q3 		– Sell
-1,842
Closed -$9.57K – 4462
2023
Q2 		$9.57K Hold
1,842
– – ﹤0.01% 4480
2023
Q1 		$11.8K Hold
1,842
– – ﹤0.01% 4509
2022
Q4 		$11.5K Hold
1,842
– – ﹤0.01% 4561
2022
Q3 		$16K Buy
+1,842
New +$15.5K ﹤0.01% 4578

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust's ABVC Position: Q2 2026 in Review

Northern Trust increased its ABVC BioPharma (ABVC) stake by 52% in Q2 2026, buying an estimated $20.6K and bringing the position to 48,643 shares worth $76.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4181.

Northern Trust first reported a position in ABVC in Q3 2022 and has held it in 13 quarters since. The position peaked at $82.6K in Q2 2025. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Northern Trust held 48,643 shares of ABVC BioPharma worth $76.9K as of Q2 2026.
  • Northern Trust bought 16,556 ABVC BioPharma shares in Q2 2026, an estimated $20.6K.
  • ABVC BioPharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4181 holding.
  • Northern Trust first reported a position in ABVC BioPharma in Q3 2022 and has held it in 13 quarters since.
  • Northern Trust's ABVC BioPharma position peaked at $82.6K in Q2 2025.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.